Qi Cao

Qi Cao, PhD, is a Professor in the Department of Urology at Northwestern University Feinberg School of Medicine. With over 15 years of expertise in prostate cancer and epigenetics, Cao has published over 30 peer-reviewed studies. Current research focuses on therapeutic targets like EZH2 and BMI1, with pharmaceutical companies developing specific inhibitors.

• BS: Peking University (1998)
• MS: Peking University, China (2001)
• PhD: University of Michigan (2008)
• Postdoctoral Fellow: University of Michigan, Cancer and Epigenetics (2012)

Cao’s work identifies epigenetic markers (e.g., EZH2, miR-101) for aggressive cancers, reveals oncogenic mechanisms via Polycomb complexes, and explores RNA modifications in tumor progression. Recent publications address lncRNA functions and metabolic therapies in prostate cancer.

Notable awards include multiple Prostate Cancer SPORE grants, H Foundation and Polsky Institute pilot awards, and a DOD Idea Development Award. Cao is affiliated with the Robert H. Lurie Comprehensive Cancer Center and Simpson Querrey Institute for Epigenetics.

• Member, Serican Academy of Urology (2023 - Present)
• Member, SBUR (2017 - Present)
• Member, AACR (2008 - Present)

The Qi Cao Lab investigates prostate cancer progression and therapeutic strategies, collaborating with institutions like the Department of Defense and NIH. Industry relationships are disclosed per Feinberg’s integrity policies.